Evaluation of the polymorphic forms of ritonavir and lopinavir in raw materials and co-milled systems.

ABSTRACT: Recently, the U.S. Food and Drug Administration (FDA) approved the first oral antiviral drug to treat mild to moderate cases of coronavirus disease. The combination of nirmatrelvir with an already used protease inhibitor class drug, ritonavir, has led to Paxlovid®. Several studies considered drug repositioning as the first trial for new drugs. The precise identification and quantification of polymorphs in raw materials and finished products are important to researchers involved in pharmaceutical development and quality control processes. In this work, we study the solid-state behavior of the antiretroviral drugs ritonavir and lopinavir in raw materials and in milled compositions. The results indicate that mixtures of ritonavir Forms I and II are found in different batches of raw materials

SUBMITTER: Moreira Pinheiro LB 

PROVIDER: S-EPMC9585847 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature